The performance of companies tied to Sildenafil's legacy presents a challenging investment picture . While the initial boom generated substantial returns , generic competition have significantly diminished sales . Investing in related pharmaceutical firms now requires a discerning assessment of intellectual property safeguards, evolving patient tre